Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lu AG22515
- Development stage
- Phase 1
- Lead developer
- Lundbeck
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous Infusion
01
Overview
Lu AG22515 is a recombinant fusion antibody designed as a bispecific molecule targeting CD40 ligand (CD40L) and human serum albumin. It consists of anti-CD40L single-chain variable fragments (scFvs) fused to an anti-human serum albumin Fab fragment. The drug acts as a CD40 ligand inhibitor and is being developed primarily for the treatment of thyroid eye disease (TED), also known as Graves ophthalmopathy—an autoimmune inflammatory disorder associated with Graves' disease that causes inflammation and swelling behind the eyes leading to proptosis (eye bulging). The mechanism involves modulation of immune responses by inhibiting the interaction between CD40L and its receptor, which plays a key role in autoimmune pathogenesis. Lu AG22515 is currently in Phase 1 clinical trials for TED/Graves ophthalmopathy[3][4][5].
- Other names
- Lu-AG22515Lu-AG-22515Lu-AG 22515APB-A1APB-A-1APB-A 1
02
Targets
CD40LG (CD40 ligand extracellular domain)
Beyond the preview
Go deeper on Lu AG22515.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lu AG22515.